Zuragard is a drug owned by Zurex Pharma. It is protected by 7 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 24, 2036. Details of Zuragard's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9844654 | Medical skin applicator apparatus |
Apr, 2036
(11 years from now) | Active |
| US10688291 | Medical skin applicator apparatus |
Dec, 2034
(10 years from now) | Active |
| US8389583 | Antimicrobial compositions and methods of use |
Aug, 2029
(4 years from now) | Active |
| US8703828 | Antimicrobial compositions and methods of use |
May, 2028
(3 years from now) | Active |
| US9629368 | Antimicrobial compositions and methods of use |
May, 2028
(3 years from now) | Active |
| US8226971 | Catheter lock solution comprising citrate and a paraben |
May, 2025
(4 months from now) | Active |
| US9011897 | Catheter lock solution comprising citrate and a paraben |
Feb, 2025
(a month from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zuragard's patents.
Latest Legal Activities on Zuragard's Patents
Given below is the list of recent legal activities going on the following patents of Zuragard.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| 11.5 yr surcharge- late pmt w/in 6 mo, Small Entity | 06 Mar, 2024 | US8226971 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 06 Mar, 2024 | US8226971 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 26 Dec, 2023 | US10688291 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Oct, 2022 | US9011897 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 06 Oct, 2021 | US8703828 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Jun, 2021 | US9844654 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Sep, 2020 | US9629368 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 21 Aug, 2020 | US8389583 |
| Patent Issue Date Used in PTA Calculation Critical | 23 Jun, 2020 | US10688291 |
| Recordation of Patent Grant Mailed Critical | 23 Jun, 2020 | US10688291 |
FDA has granted several exclusivities to Zuragard. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zuragard, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zuragard.
Exclusivity Information
Zuragard holds 2 exclusivities. All of its exclusivities have expired in 2024. Details of Zuragard's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2022 |
| M(M-268) | Jun 24, 2024 |
US patents provide insights into the exclusivity only within the United States, but Zuragard is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zuragard's family patents as well as insights into ongoing legal events on those patents.
Zuragard's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zuragard's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 24, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zuragard Generics:
There are no approved generic versions for Zuragard as of now.
Alternative Brands for Zuragard
Zuragard which is used for skin preparation prior to surgery., has several other brand drugs in the same treatment category and using the same active ingredient (Isopropyl Alcohol). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Becton Dickinson Co |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Isopropyl Alcohol. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| 3m Health Care |
| |||
| Becton Dickinson Co |
| |||
| Prof Dspls |
|
About Zuragard
Zuragard is a drug owned by Zurex Pharma. It is used for skin preparation prior to surgery. Zuragard uses Isopropyl Alcohol as an active ingredient. Zuragard was launched by Zurex Pharma in 2019.
Approval Date:
Zuragard was approved by FDA for market use on 26 April, 2019.
Active Ingredient:
Zuragard uses Isopropyl Alcohol as the active ingredient. Check out other Drugs and Companies using Isopropyl Alcohol ingredient
Treatment:
Zuragard is used for skin preparation prior to surgery.
Dosage:
Zuragard is available in solution form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 70% | SOLUTION | Over the counter | TOPICAL |